» Articles » PMID: 22156481

Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-endemic Area

Overview
Journal Digestion
Specialty Gastroenterology
Date 2011 Dec 14
PMID 22156481
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: We investigated the relative etiological role of prior hepatitis B virus (HBV) infection and nonalcoholic fatty liver disease (NAFLD) in the development of non-B non-C, non-alcohol or specific cause-related hepatocellular carcinoma (NBNC-NA-NS HCC) in an HBV-endemic area of Korea.

Methods: A total of 329 patients with NBNC-NA-NS HCC were enrolled in this study. Prior HBV infection was defined as the presence of isolated IgG hepatitis B core antibody (anti-HBc), and NAFLD was diagnosed by the findings from the imaging in the absence of a history of excessive alcohol consumption.

Results: Prior HBV infection was the most common cause of underlying liver disease (76.6%). Only 8.2% of the patients had NAFLD as the only risk factor and the same proportion of patients had evidence of both prior HBV infection and NAFLD. Patients without definitive causes accounted for 7.0% of the cases. During the past 10 years, the relative proportion of isolated IgG anti-HBc-positive HCC decreased significantly from 86.6% in 2001-2005 to 67.4% in 2006-2010 (p < 0.0001) and that of NAFLD-related HCC increased from 3.8% to 12.2% in the same period, respectively (p = 0.008). The mean age of NAFLD-related HCC patients (67.3 years) was significantly older than that of HCC patients related to prior HBV infection (61.2 years, p < 0.001).

Conclusions: NAFLD-related HCC increased significantly while HCC related to prior HBV infection decreased during the past 10 years in an HBV-endemic area of Korea; however, the relative etiological role of prior HBV infection was still greater than that of NAFLD in the development of NBNC-NA-NS HCC.

Citing Articles

International perspectives on LI-RADS.

Kierans A, Aguirre D, Krishan S, Lee J, Ronot M, Wang J Abdom Radiol (NY). 2024; .

PMID: 39699666 DOI: 10.1007/s00261-024-04729-3.


Global Epidemiology of Hepatocellular Carcinoma.

Singh S, Madke T, Chand P J Clin Exp Hepatol. 2024; 15(2):102446.

PMID: 39659901 PMC: 11626783. DOI: 10.1016/j.jceh.2024.102446.


Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.

Mak L, Liu K, Chirapongsathorn S, Yew K, Tamaki N, Rajaram R Nat Rev Gastroenterol Hepatol. 2024; 21(12):834-851.

PMID: 39147893 DOI: 10.1038/s41575-024-00967-4.


A Comparison of Presentation, Treatment, and Survival After Hepatocellular Carcinoma of Viral and Non-Viral Etiology in Damietta, Egypt, 2007-2019.

Jean K, Tawheed A, Luong Nguyen L, Heikal T, Eldaly U, Gaber Elhadidy N J Hepatocell Carcinoma. 2024; 11:997-1004.

PMID: 38835726 PMC: 11149647. DOI: 10.2147/JHC.S455832.


Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.

Kim D J Liver Cancer. 2024; 24(1):62-70.

PMID: 38523466 PMC: 10990659. DOI: 10.17998/jlc.2024.03.13.